| abstract |
The present invention provides a stable, continuous human myeloma cell line which is capable of hybridization with antibody-producing cells of humans and other animals, the cell line being a mutant of GM 1500 human B cells and being deficient in hypoxanthine phosphoribosyltransferase. The invention also comprises processes for the production of hybrid cells employing the stable, HPRT-deficient human myeloma cell line, and processes for the production of antibodies employing such hybrid cells. |